Pipeline

Our R&D strategy leverages our validated technology platform with a focus on expanding beyond our existing core expertise in COVID-19, influenza, and COVID-19-Influenza Combination (CIC) vaccines.

We are identifying early-stage pipeline and innovation expansion opportunities to support long-term growth. Early work will include strategically moving forward with RSV and pandemic flu, which are disease areas that leverage our existing experience and internal expertise in infectious diseases. Our next step is to identify other infectious disease areas that are or could become vaccine-preventable, meet other guiding principles, and for which our technology could possess differentiating attributes. Finally, we will potentially expand more broadly beyond infectious diseases, by leveraging specialized scientific knowledge and robust translational models to evaluate a range of chronic diseases where our technology could lead to the development of preclinical constructs to advance to proof of mechanism and proof of concept studies, and beyond.